Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03UDF
|
|||
Drug Name |
LOXO-195
|
|||
Synonyms |
OEBIHOVSAMBXIB-SJKOYZFVSA-N; LOXO195; UNII-0J45910S3X; 2097002-61-2; 0J45910S3X; LOXO-195 (S racemic); LOXO 195; SCHEMBL18823882; EX-A1873; HY-101977; CS-0022378; Cas registry number 2097002-61-2 ~1~1 C20 H21 F N6 O 10H-5,7-ethenopyrazolo(3,4-d)pyrido(2,3-k)pyrrolo(2,1-m)(1,3,7)triazacyclotridecin-10-one, 17-fluoro-1,2,3,11,12,13,14,18b-octahydro-12-methyl-, (12R,18bR)-; 12H-15,17-Ethenopyrazolo[3,4-d]pyrido[2,3-k]pyrrolo[2,1-m][1,3,7]triazacyclotridecin-12-one, 5-fluoro-1,2,3,3a,8,9,10,11-octahydro-10-methyl-, (3aR,10R)-; (13E,14E,22R,6R
Click to Show/Hide
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
Company |
Bayer Pharmaceuticals Whippany, NJ; Loxo Oncology Stamford, CT
|
|||
Structure |
Download2D MOL |
|||
Formula |
C20H21FN6O
|
|||
Canonical SMILES |
CC1CCC2=C(C=C(C=N2)F)C3CCCN3C4=NC5=C(C=NN5C=C4)C(=O)N1
|
|||
InChI |
1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12-,17-/m1/s1
|
|||
InChIKey |
OEBIHOVSAMBXIB-SJKOYZFVSA-N
|
|||
CAS Number |
CAS 2097002-61-2
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tropomyosin-related kinase A (TrkA) | Target Info | Inhibitor | [1] |
KEGG Pathway | MAPK signaling pathway | |||
Endocytosis | ||||
Apoptosis | ||||
Neurotrophin signaling pathway | ||||
Inflammatory mediator regulation of TRP channels | ||||
Pathways in cancer | ||||
Transcriptional misregulation in cancer | ||||
Thyroid cancer | ||||
Central carbon metabolism in cancer | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
Pathway Interaction Database | Neurotrophic factor-mediated Trk receptor signaling | |||
Reactome | Frs2-mediated activation | |||
ARMS-mediated activation | ||||
NGF-independant TRKA activation | ||||
PI3K/AKT activation | ||||
WikiPathways | MAPK Signaling Pathway | |||
BDNF signaling pathway | ||||
Integrated Pancreatic Cancer Pathway | ||||
NGF signalling via TRKA from the plasma membrane |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.